Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors

Core Viewpoint - A class action has been initiated for investors of UniQure N.V. who purchased securities during the specified class period, following a significant drop in stock price due to FDA feedback regarding their investigational gene therapy AMT-130 [1][3]. Group 1: Class Action Details - The Portnoy Law Firm is advising UniQure investors to file a lead plaintiff motion by April 13, 2026, if they bought securities between September 24, 2025, and October 31, 2025 [1]. - Investors can contact attorney Lesley F. Portnoy for legal rights discussions and to join the case [2]. Group 2: FDA Feedback and Stock Impact - On November 3, 2025, UniQure announced that the FDA no longer considers the data from Phase I/II studies of AMT-130 adequate for a Biologics License Application (BLA) submission, marking a significant shift from previous communications [3]. - Following this announcement, UniQure's stock price plummeted by $33.40 per share, or 49.34%, closing at $34.29 per share [3].